Inovio Pharmaceuticals, Inc.

Inovio Pharmaceuticals, Inc.

1.73
CHF
+0.56
(+48.50%)
-0.75EPS
Mar 02Next Earn

Important Dates

Inovio Pharmaceuticals, Inc.'s next confirmed earnings release is scheduled for March 2, 2027.

Earnings Date3/2/2027

Share Statistics

As of September 30, 2026, Inovio Pharmaceuticals, Inc. has 110.18M shares outstanding.

Shares Outstanding110.18M

Financial Position

As of September 30, 2026, Inovio Pharmaceuticals, Inc. maintains a current ratio of 0.57, meaning it holds 0.6x the short-term assets needed to cover near-term liabilities.

Current Ratio0.57
Quick Ratio0.54
Debt / Equity-21.47
Debt / EBITDA-0.10

Financial Efficiency

CHF

These figures cover the twelve months ended September 30, 2026. Return on assets (ROA) is negative at -109.84, reflecting losses generated across the asset base. The company generates approximately 2,226.52 in revenue per employee across its workforce of 112.00, a quick read on workforce productivity versus industry peers.

Return on Assets (ROA)-109.84
Revenue Per Employee2,226.52
Employee Count112.00

Stock Price Statistics

As of the close on November 2, 2026, Inovio Pharmaceuticals, Inc.'s stock has declined approximately 2.26% over the past 52 weeks.

52-Week Price Change-2.26%

Income Statement

CHF

Over the twelve months ended September 30, 2026, Inovio Pharmaceuticals, Inc. generated 249,370.12 in revenue and converted that into -59.35M in net income, yielding earnings per share of -0.75. EBITDA reached -62.18M, while operating income came in at -64.72M.

Revenue249,370.12
Operating Income-64.72M
Pretax Income-59.35M
Net Income-59.35M
EBITDA-62.18M
EBIT-64.72M
Earnings Per Share (EPS)-0.75

Balance Sheet

CHF

As of September 30, 2026, Inovio Pharmaceuticals, Inc. holds 40.35M in cash and equivalents against 6.08M in total debt, resulting in a net debt position of -39.18M. Total book value stands at -28.30M, with working capital of -31.72M providing operational flexibility.

Cash & Cash Equivalents40.35M
Total Debt6.08M
Net Debt-39.18M
Equity (Book Value)-28.30M
Book Value Per Share-0.26
Working Capital-31.72M

Cash Flow

CHF

Inovio Pharmaceuticals, Inc. produced -61.97M in operating cash flow over the twelve months ended September 30, 2026. After subtracting -106,325.25 in capital expenditures, free cash flow totaled -62.08M - equivalent to -0.78 per share.

Operating Cash Flow-61.97M
Capital Expenditures-106,325.25
Free Cash Flow-62.08M
FCF Per Share-0.78

Margins

These figures cover the twelve months ended September 30, 2026. The operating margin of -25,953.76 and net profit margin of -23,798.90 provide insight into operational efficiency.

Operating Margin-25,953.76
Pretax Margin-23,798.90
Profit Margin-23,798.90
EBITDA Margin-24,934.34

Stock Splits

Inovio Pharmaceuticals, Inc.'s most recent stock split took place on January 25, 2024 with a 12:1 split ratio.

Last Split Date1/25/2024
Split Ratio12:1